Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

VK2735-101 oral part C

43 evidence topics · 7 sources

Objective
Location and study date
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Primary completion (actual)“2024-11-04”
Study completion (actual)“2024-12-03”
Site city“Adelaide”
Study design
Eligibility criteria
Age range in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Minimum age“18 Years”
Maximum age“65 Years”
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Oral formulation: participants analyzed by cohort
GroupEfficacy populationSafety population
Placebo“(n=18)”“(n=19)”
VK2735 2.5 mg“(n=8)”“(n=8)”
VK2735 5 mg“(n=6)”“(n=7)”
VK2735 10 mg“(n=6)”“(n=6)”
VK2735 20 mg“(n=8)”“(n=8)”
VK2735 40 mg“(n=7)”“(n=8)”
VK2735 60 mg“(n=9)”“(n=9)”
VK2735 80 mg“(n=9)”“(n=9)”
VK2735 100 mg“(n=9)”“(n=9)”
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
FieldRegistry value
Enrollment (actual)“92”
Description of analysis sets
Results
Participant disposition
Oral formulation: early study discontinuation by cohort
GroupDiscontinued study early
Placebo (n=19)“2 (11%)”
VK2735 2.5 mg (n=8)“0 (0%)”
VK2735 5 mg (n=7)“1 (14%)”
VK2735 10 mg (n=6)“0 (0%)”
VK2735 20 mg (n=8)“0 (0%)”
VK2735 40 mg (n=8)“1 (13%)”
VK2735 60 mg (n=9)“1 (11%)”
VK2735 80 mg A (n=9)“1 (11%)”
VK2735 80 mg B (n=9)“0 (0%)”
VK2735 100 mg (n=9)“0 (0%)”
Baseline characteristics
Oral formulation: mean baseline characteristics by cohort
GroupAgeSex, M:F (%)White (%)Weight (kg)BMI (kg/m2)
Placebo (n=19)“38”“47:53”“68”“99”“36”
VK2735 2.5 mg (n=8)“34”“63:37”“75”“102”“36”
VK2735 5 mg (n=7)“29”“43:57”“71”“97”“34”
VK2735 10 mg (n=6)“35”“17:83”“100”“97”“36”
VK2735 20 mg (n=8)“35”“63:37”“88”“111”“36”
VK2735 40 mg (n=8)“33”“25:75”“63”“89”“33”
VK2735 60 mg (n=9)“44”“33:67”“89”“108”“37”
VK2735 80 mg (n=9)“44”“56:44”“100”“102”“35”
VK2735 100 mg (n=9)“44”“44:56”“67”“103”“35”
Efficacy results
Oral formulation: change in body weight by cohort at day 28
MeasurePlacebo (n=18)2.5 mg (n=8)5 mg (n=6)10 mg (n=6)20 mg (n=8)40 mg (n=7)60 mg (n=9)80 mg (n=9)100 mg (n=9)
Mean baseline body weight“98.3 kg”“102.3 kg”“95.3 kg”“97.1 kg”“111.3 kg”“90.0 kg”“107.7 kg”“102.0 kg”“102.7 kg”
Mean change from baseline body weight“-1.4 kg”“-0.3 kg”“-0.8 kg”“-1.3 kg”“-3.6 kg”“-4.8 kg”“-4.4 kg”“-5.3 kg”“-8.2 kg”
Mean percent change from baseline“-1.4 %”“-0.3 %”“-0.8 %”“-1.1 %”“-3.5 %”“-5.1 %”“-4.1 %”“-5.2 %”“-8.2 %”
Placebo-adjusted mean percent change from baseline“-”“1.0 %”“0.6 %”“0.3 %”“-2.2 %”“-3.7 %”“-2.7 %”“-3.9 %”“-6.8 %”
p-value vs. placebo“-”“-”“-”“-”“0.0174”“0.0001”“0.0026”“<0.0001”“<0.0001”
Percent reporting at least 5% weight loss“0 %”“0 %”“0 %”“0 %”“25 %”“57 %”“38 %”“63 %”“100 %”
p-value vs. placebo for at least 5% weight loss“-”“-”“-”“-”“0.0933”“0.0033”“0.0243”“0.0011”“<0.0001”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Oral formulation: adverse event summary by cohort
EventPlacebo (n=19)2.5 mg (n=8)5 mg (n=7)10 mg (n=6)20 mg (n=8)40 mg (n=8)60 mg (n=9)80 mg A (n=9)80 mg B (n=9)100 mg (n=9)
Treatment-emergent adverse events“16 (84%)”“6 (75%)”“6 (86%)”“4 (67%)”“6 (75%)”“7 (88%)”“9 (100%)”“9 (100%)”“8 (89%)”“9 (100%)”
Drug-related treatment-emergent adverse events“11 (58%)”“4 (50%)”“4 (57%)”“3 (50%)”“4 (50%)”“7 (88%)”“6 (67%)”“9 (100%)”“7 (78%)”“9 (100%)”
Serious adverse events“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“0 (0%)”“1 (11%)”“0 (0%)”“0 (0%)”“0 (0%)”
Study limitations
Summary: study limitations

VK2735-101 Part C was the first administration of the oral tablet formulation, in otherwise healthy adults with a body mass index of at least 30 kg/m2 who took VK2735 once daily for 28 days with follow-up to day 57. Safety and tolerability were the primary objectives, and body weight was an exploratory measure. Each VK2735 cohort had 6 to 9 participants and the pooled placebo group had 17 to 19, depending on the analysis; the every-other-day cohort at 80 mg had 9 participants. The tablet doses studied (2.5 to 100 mg) differ from the doses carried into phase 3 (27.5, 35, and 55 mg), and 28 days of dosing does not show where weight loss plateaus. Part C has no registry record of its own: the ClinicalTrials.gov record for NCT05203237 describes Part C in its detailed description but registers a single primary outcome, safety after single subcutaneous doses over 8 days, and reports an actual enrollment of 92 for Parts A, B, and C, the same number the poster reports as randomized in Part C alone. The interim release of March 2024 stated that “no serious adverse events (SAEs) have been reported to date” for cohorts through 40 mg; the poster reports one serious adverse event in the 60 mg cohort (1 of 9, 11%) without describing it. Results are available only in press releases, a corporate presentation, and a congress poster, with no peer-reviewed publication and no results posted to the registry.